A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin.

Oluwadara OlatokeVladimir Zah Filip Stanicic Djurdja VukicevicPlatonas YfantopoulosChristy ThompsonMichael K DeGeorgeSteven Passik

Published in: ClinicoEconomics and outcomes research : CEOR (2022)

This study suggests that Xtampza ER may result in lower healthcare costs than OxyContin for a population of chronic pain patients switching from immediate release oxycodone based on real-world data.

Keyphrases

healthcare
end stage renal disease
chronic pain
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
pain management
social media